The direct medical cost of type 2 diabetes.

OBJECTIVE To describe the direct medical costs associated with type 2 diabetes, as well as its treatments, complications, and comorbidities. RESEARCH DESIGN AND METHODS We studied a random sample of 1,364 subjects with type 2 diabetes who were members of a Michigan health maintenance organization. Demographic characteristics, duration of diabetes, diabetes treatments, glycemic control, complications, and comorbidities were assessed by surveys and medical chart reviews. Annual resource utilization and costs were assessed using health insurance claims. The log-transformed annual direct medical costs were fitted by multiple linear regression to indicator variables for demographics, treatments, glycemic control, complications, and comorbidities. RESULTS The median annual direct medical costs for subjects with diet-controlled type 2 diabetes, BMI 30 kg/m(2), and no microvascular, neuropathic, or cardiovascular complications were 1,700 dollars for white men and 2,100 dollars for white women. A 10-kg/m(2) increase in BMI, treatment with oral antidiabetic or antihypertensive agents, diabetic kidney disease, cerebrovascular disease, and peripheral vascular disease were each associated with 10-30% increases in cost. Insulin treatment, angina, and MI were each associated with 60-90% increases in cost. Dialysis was associated with an 11-fold increase in cost. CONCLUSIONS Insulin treatment and diabetes complications have a substantial impact on the direct medical costs of type 2 diabetes. The estimates presented in this model may be used to analyze the cost-effectiveness of interventions for type 2 diabetes.

[1]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[2]  F. Tediosi,et al.  Costs of diabetes. A methodological analysis of the literature. , 1999, PharmacoEconomics.

[3]  J. Caro,et al.  Lifetime costs of complications resulting from type 2 diabetes in the U.S. , 2002, Diabetes care.

[4]  E. Dasbach,et al.  The longitudinal cost of end-stage renal disease in persons with diabetes in the United States , 2004 .

[5]  P. M. Jonsson,et al.  Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden. , 2000, Diabetes research and clinical practice.

[6]  P. Donnan,et al.  Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. , 2000, Diabetes care.

[7]  E H Wagner,et al.  Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.

[8]  A. Bagust,et al.  An economic model of the long-term health care burden of Type II diabetes , 2001, Diabetologia.

[9]  M A Koopmanschap,et al.  Resource consumption and costs in Dutch patients with Type 2 diabetes mellitus. Results from 29 general practices , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[10]  C. Östenson,et al.  Direct medical costs for patients with type 2 diabetes in Sweden , 2000, Journal of internal medicine.

[11]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[12]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[13]  N. Powe,et al.  Predicting expenditures for Medicare beneficiaries with diabetes. A prospective cohort study from 1994 to 1996. , 1999, Diabetes care.

[14]  G. Nichols,et al.  The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. , 2002, Diabetes care.

[15]  H. Glauber,et al.  Impact of cardiovascular disease on health care utilization in a defined diabetic population. , 1994, Journal of clinical epidemiology.

[16]  J. Selby,et al.  Excess Costs of Medical Care for Patients With Diabetes in a Managed Care Population , 1997, Diabetes Care.

[17]  Jonathan B. Brown,et al.  The progressive cost of complications in type 2 diabetes mellitus. , 1999, Archives of internal medicine.

[18]  G. Nichols,et al.  Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. , 1999, Diabetes care.

[19]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[20]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[21]  J. O'brien,et al.  Direct Medical Costs of Complications Resulting From Type 2 Diabetes in Hie U.S. , 1998, Diabetes Care.

[22]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.